Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Abroad (travel likely)RecruitingPHASE2
Conditions
Antiphospholipid Syndrome · Thrombocytopenia · Treatment
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality, China
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China
Study leads
Lei Zhang, MD
Principal Investigator
Chinese Academy of Medical Science and Blood Disease Hospital